Abivax Bounces Back: Shares Wipe Out a Month of Losses After Cancer Safety Fears Subside

French biotech company Abivax experienced a dramatic single-day recovery on June 30, 2026, with its shares jumping more than 38% after updated Phase 3 clinical data helped dispel serious cancer-related safety concerns that had previously wiped out nearly half the company's market value.

The sharp rebound was directly tied to new clinical findings for obefazimod, Abivax's flagship drug candidate targeting ulcerative colitis. The latest data demonstrated sustained remission rates among patients and — critically — no new safety red flags that would further alarm investors or regulators.

What Triggered the Initial Collapse

The trouble began on June 2, when Abivax's stock plummeted 43% in a single session. Early trial results had suggested an elevated rate of malignancies — or cancerous growths — among patients receiving obefazimod. That revelation sent shockwaves through the investment community and raised doubts about the drug's future regulatory path.

However, the company moved quickly to address those concerns. On Sunday, June 28, Abivax released an expanded Phase 3 dataset focusing specifically on patients who had not responded to initial treatment. The updated analysis revealed that malignancy rates observed in this group fell within the typical range seen in ulcerative colitis patients more broadly — a finding that significantly defused the alarm that had driven June's selloff. The entire sequence of events — the crash and the recovery — is clearly visible on the stock's one-month price chart.

Efficacy Results Add to the Bullish Case

Beyond the safety reassurance, the new data also reinforced obefazimod's effectiveness. Among treatment-resistant patients, 37.2% achieved clinical remission by week 44, while 34.5% reached endoscopic remission. These numbers strengthened the argument that the drug can deliver meaningful results even in harder-to-treat cases.

It is worth noting that Abivax shares have now surged more than 1,730% over the trailing twelve-month period, making it one of the more remarkable performers in the biotech space despite the recent turbulence.

Analysts Remain Divided on Remaining Risk

Not everyone on Wall Street is fully convinced that the storm has passed. Analysts responded to the updated data with notably different conclusions.

Citizens took an optimistic stance, raising its price target on Abivax to $187 while maintaining an Outperform rating. The firm highlighted the drug's strong placebo-adjusted remission benefit as a key reason for confidence.

Wedbush, on the other hand, approached the situation more carefully. The firm upgraded its rating from Underperform to Neutral — a positive shift — but simultaneously cut its price target to $90. Wedbush flagged unresolved questions around malignancy risks at the 50 mg dosage level as a potential obstacle during the regulatory review process.

Looking Ahead: FDA Filing on the Horizon

Abivax has confirmed that it still intends to submit a New Drug Application to the U.S. Food and Drug Administration during the fourth quarter of 2026. That upcoming milestone means the stock is likely to remain highly sensitive to any additional clinical or safety data that emerges in the months leading up to the filing. Investors and analysts will be watching closely for any further developments that could sway the regulatory outcome.